Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in ...

Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

Bristol-Myers Squibb Company BMY reported first-quarter 2025 adjusted earnings per share (EPS) of $1.80, which comfortably beat the Zacks Consensus Estimate of $1.51. In the year-ago quarter, BMY ...

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

Drugmakers have been warned that the Trump Administration is considering linking U.S. medicine prices to lower amounts paid ...

Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a $13 ...

DEAR DR. ROACH: My 86-year-old mother wears hearing aids, has tinnitus and is constantly dizzy. She also has atrial ...

Pfizer just pulled the plug on its oral weight-loss pill danuglipron after a liver injury case raised safety alarms. This decision underscores how the path from lab to medicine cabinet is riddled with ...

Most of these medications have "dizziness" as a side effect. It is possible that her medications are the cause of her ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 ...

Conspicuously anglo human characters resemble the generic design often seen in low-rent CG fare produced overseas: large heads with pristine skin and pronounced facial features. To explain ...